TuHURA Biosciences (HURA) Expected to Announce Quarterly Earnings on Tuesday

TuHURA Biosciences (NASDAQ:HURAGet Free Report) is projected to issue its quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

TuHURA Biosciences Trading Up 1.0%

Shares of NASDAQ HURA opened at $3.97 on Monday. The firm’s 50-day moving average is $3.50. TuHURA Biosciences has a 52 week low of $1.80 and a 52 week high of $7.93.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their price objective on TuHURA Biosciences from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, April 3rd.

Read Our Latest Research Report on TuHURA Biosciences

Institutional Trading of TuHURA Biosciences

An institutional investor recently bought a new position in TuHURA Biosciences stock. Bank of America Corp DE bought a new stake in TuHURA Biosciences (NASDAQ:HURAFree Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 14,314 shares of the company’s stock, valued at approximately $59,000. 0.62% of the stock is owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

(Get Free Report)

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.

Featured Stories

Earnings History for TuHURA Biosciences (NASDAQ:HURA)

Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.